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CD8+ T cells are believed to play an important role in multiple
sclerosis (MS), yet their role in MS pathogenesis remains poorly
defined. Although myelin proteins are considered potential auto-
antigenic targets, prior studies of myelin-reactive CD8+ T cells in
MS have relied on in vitro stimulation, thereby limiting accurate
measurement of their ex vivo precursor frequencies and pheno-
types. Peptide:MHC I tetramers were used to identify and validate
5 myelin CD8+ T cell epitopes, including 2 newly described deter-
minants in humans. The validated tetramers were used to measure
the ex vivo precursor frequencies and phenotypes of myelin-specific
CD8+ T cells in the peripheral blood of untreatedMS patients and HLA
allele-matched healthy controls. In parallel, CD8+ T cell responses
against immunodominant influenza epitopes were also measured.
There were no differences in ex vivo frequencies of tetramer-
positive myelin-specific CD8+ T cells between MS patients and con-
trol subjects. An increased proportion of myelin-specific CD8+ T cells
in MS patients exhibited a memory phenotype and expressed CD20
compared to control subjects, while there were no phenotypic differ-
ences observed among influenza-specific CD8+ T cells. Longitudinal
assessments were also measured in a subset of MS patients sub-
sequently treated with anti-CD20 monoclonal antibody therapy.
The proportion of memory and CD20+ CD8+ T cells specific for certain
myelin but not influenza epitopes was significantly reduced follow-
ing anti-CD20 treatment. This study, representing a characterization
of unmanipulated myelin-reactive CD8+ T cells in MS, indicates these
cells may be attractive targets in MS therapy.
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The adaptive immune system, including CD4+ T cells and Bcells, has long been implicated in the pathogenesis of mul-
tiple sclerosis (MS) (1, 2), a chronic inflammatory demyelinating
disease of the central nervous system (CNS). Although CD8+ T
cells are primarily recognized for their cytotoxic function in an-
tiviral and antitumor immunity, compelling evidence suggests they
have an important role in MS. CD8+ T cells are enriched in the
perivascular space and leading edge of MS white matter lesions
(3–7), where they greatly outnumber CD4+ T cells (4, 6, 8, 9) and
are also present in the majority of cortical lesions (10). In contrast
to CD4+ T cells, CD8+ T cells in MS lesions are clonally expanded
(11–13), suggesting antigen-driven proliferation. In individual MS
patients, common clonal CD8+ T cell populations are present
within the lesions and normal-appearing white matter (11, 14).
Several MHC I alleles, including HLA-A*02:01 (HLA-A2) and
HLA-A*03:01 (HLA-A3), are known to alter MS susceptibility
(15, 16). MHC I is specifically up-regulated in microglia, macro-
phages, astrocytes, and oligodendrocytes of acute MS lesions (17).
In addition, CD8+ T cells in MS lesions are found in direct contact
with oligodendrocytes (8), suggesting CD8+ T cells may contribute
directly to demyelinating pathology.
Myelin is considered a putative target autoantigen in MS (18),
and myelin-specific CD8+ T cells are well known to contribute to
CNS pathology in experimental autoimmune encephalomyelitis
(EAE) (19–23). A number of studies have described the reactivity
of human CD8+ T cells against myelin antigens (24–30); however,
reports are conflicting whether myelin-specific CD8+ T cell re-
sponses differ between MS patients and controls (24, 27–30).
Much of the prior work was limited by a reliance on functional as-
says, precluding the sensitive detection of unmanipulated epitope-
specific CD8+ T cell populations.
To overcome these limitations, we generated a large panel of
myelin peptide:MHC I (pMHC I) tetramers, considered the gold
standard for detection of antigen-specific CD8+ T cells (31). We
sought to identify and validate myelin-specific CD8+ T cell epi-
topes restricted by HLA-A2 and HLA-A3 alleles by combining
pMHC I tetramer detection and functional reactivity to cognate
myelin antigen. Using this approach, we validated 5 myelin CD8+ T
cell epitopes, including 2 epitopes that have not been previously
reported in humans. Combinatorial tetramer staining (32, 33)
and enrichment (34) strategies were employed to identify myelin-
specific CD8+ T cells ex vivo from the peripheral blood. In
comparison, we also measured CD8+ T cell responses to
immunodominant epitopes of influenza, a widely encountered
foreign antigen. We observed that the frequencies of myelin-
specific CD8+ T cells did not differ between MS patients and
control subjects for any of the myelin epitopes. We also assessed
the phenotypes of these CD8+ T cell populations by the expression
of memory markers as well as CD20, which is increased on memory
CD8+ T cells in MS patients and reduced following anti-CD20
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monoclonal antibody (mAb) treatment (35, 36). Interestingly,
memory myelin-specific CD8+ T cells were increased in MS
patients compared to controls, indicating prior exposure to anti-
gen. The proportion of myelin-specific CD8+ T cells expressing
CD20 was also increased in MS patients, consistent with an in-
creased activation state. No such phenotypic differences were
observed between influenza-specific CD8+ T cells. Myelin-specific
CD8+ T cells with the highest memory phenotype and CD20 ex-
pression at baseline had a significant reduction in these markers
following anti-CD20 mAb treatment. These studies suggest that
myelin-specific CD8+ T cells have an activated phenotype in MS
patients, thereby permitting their preferential depletion by anti-
CD20 mAb therapy.
Results
Identification of Myelin CD8+ T Cell Epitopes. A tetramer-based
expansion protocol, previously described for the identification of
tumor neo-antigen–specific CD8+ T cells (37), was employed for
screening candidate myelin CD8+ T cell epitopes (Materials and
Methods). Screening for HLA-A2– and HLA-A3–restricted myelin
T cell epitopes was focused on 5 key myelin proteins expressed in the
CNS: proteolipid protein (PLP), myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG), myelin-associated glycopro-
tein (MAG), and 2′,3′-cyclic-nucleotide 3′-phosphodiesterase
(CNP). Candidate myelin epitopes were selected by in silico epi-
tope prediction for HLA-A2 and HLA-A3 (SI Appendix, Table
S1), followed by measurement of relative binding of individual
myelin peptides to each MHC I protein (SI Appendix, Fig. S1).
Pools of selected myelin peptides were used to stimulate pe-
ripheral blood mononuclear cells (PBMCs) from a cohort of un-
treated HLA-A2+ and HLA-A3+ relapsing–remitting MS (RR-
MS) patients. Pooled myelin tetramer-positive CD8+ T cells
were sorted, expanded with mitogen, and screened for their ability
to bind each myelin pMHC I tetramer individually (Fig. 1A). As
shown in one representative experiment (Fig. 1B), expanded
CD8+ T cells only bound to HLA-A2–restricted MOG181–189 tet-
ramer. There was no binding to the immunodominant HLA-A2–
restricted influenza A epitope M158–66, supporting specificity of
MOG181–189 tetramer binding. Functional reactivity and HLA
restriction of MOG181–189 tetramer-positive CD8
+ T cells was
demonstrated by intracellular cytokine production following stim-
ulation with cognate antigen-loaded T2 cells (see Materials and
Methods for further details) (Fig. 1C). Using this stepwise ap-
proach, 3 HLA-A2 (MOG181–189, MOG156–164, and MAG509–517)
and 2 HLA-A3 (PLP45–53 and CNP54–63) CD8
+ T cell epitopes
were validated (Fig. 1C). The determinants MOG156–164:HLA-A2,
MAG509–517:HLA-A2, and PLP45–53:HLA-A3 have previously
been described in humans (24, 25, 30). To our knowledge,
MOG181–189:HLA-A2 and CNP54–63:HLA-A3 have not been
described in humans. Of interest, MOG181–189 was previously
reported as a CD8+ T cell epitope in HLA-A2 transgenic mice
(21), and both the MOG181–189 and PLP45–53 epitopes were
pathogenic in humanized mouse models of EAE (21, 22). A po-
tential pathogenic role for these populations is supported by the
finding that all of the isolated myelin-specific CD8+ T cell
populations produced significant amounts of IFNγ, TNFα, IL-2,
GM-CSF, and CD107a (SI Appendix, Fig. S2 A and B).
Ex Vivo Frequency Analysis of Myelin CD8+ T Cells. The circulating
frequencies of autoreactive T cells in the peripheral blood are
rare (∼1 in 105 to 106 T cells) (38). We employed a combinatorial
tetramer staining (32, 33) and magnetic bead enrichment strategy
(31, 34, 39) (Fig. 2A) in order to measure multiple antigen-specific
T cells ex vivo in an accurate and sensitive manner. We measured
the ex vivo frequencies of the 5 validated myelin CD8+ T cell
determinants in the peripheral blood of a second cohort of un-
treated RR-MS patients and HLA allele-matched healthy controls
(Table 1). The immunodominant influenza epitopes M158–66
(HLA-A2) and NP265–273 (HLA-A3) were used as comparisons to
ubiquitous viral-specific CD8+ T cells. Antigen-specific CD8+ T
cells were identified from a single PBMC sample using tetramer
pools containing unique combinations of dual fluorophores (SI
Appendix, Table S2). Myelin-specific CD8+ T cells were readily
detectable in nearly all individuals. Strikingly, there were no sig-
nificant differences in the frequencies of any of the myelin-specific
CD8+ T cell populations in MS patients in comparison to HLA
allele-matched healthy controls (Fig. 2 B and C). Influenza-
specific CD8+ T cells were detected at frequencies 1 to 2 orders
of magnitude higher than those specific for myelin antigen (mean,
3.73 × 10−4 ± 0.65 and 1.33 × 10−4 ± 0.60 for HLA-A2 and HLA-
A3, respectively). Interestingly, influenza-specific (M158–66) CD8
+ T
cells in HLA-A2+ RR-MS patients were significantly increased
compared to HLA-allele matched healthy controls, but no signif-
icant difference was observed in influenza-specific CD8+ T cells
(NP265–273) in HLA-A3
+ individuals (Fig. 2 B and C).
Memory Status of Myelin-Specific CD8+ T Cells. The differentiation
states of ex vivo antigen-specific CD8+ T cells were explored fur-
ther by evaluating their CCR7 and CD45RA expression, pro-
totypic markers of naive and memory status (SI Appendix, Fig.
S4A). In comparing MS patients to control subjects, there was a
significant reduction in naive (28.1 ± 2.8% vs. 36.7 ± 3.4%, re-
spectively) and a corresponding increase in effector memory (41.2 ±
3.5% vs. 26.6 ± 2.4%, respectively) fractions in total CD8+ T
cells (i.e., irrespective of antigen specificity) in MS patients com-
pared to control subjects (SI Appendix, Fig. S4B), consistent with
prior reports (40, 41). Because of the limited numbers of antigen-
specific T cells available for phenotyping, we compared the mem-
ory status of all tetramer-positive CD8+ T cells by naive (CCR7+
CD45RA+) or memory (combined central memory CCR7+
CD45RA−, effector memory CCR7−CD45RA−, and TEMRA
CCR7− CD45RA+). Influenza-specific CD8+ T cells exhibited a
predominantly memory phenotype, and there were no differences
in memory status between MS patients and control subjects (Fig.
2D and E). As a whole, the memory status of all combined myelin-
specific CD8+ T cells in MS patients (52.2 ± 4.1%) was signifi-
cantly increased compared to controls (40.5 ± 4.4%) (Fig. 2D). In
particular, memory MOG181–189-specific CD8
+ T cells were sig-
nificantly increased in MS patients (65.1 ± 11.1%) compared to
controls (25.5 ± 11.0%) (Fig. 2E). CD8+ T cells responding to
2 additional myelin determinants, MAG509–517 and PLP45–53,
showed nonsignificant increases in memory status in MS patients
(Fig. 2E). These data suggest that although the frequencies of
myelin-specific CD8+ T cells do not differ between MS patients
and control individuals, those T cells from MS patients are more
likely to exhibit a memory phenotype.
CD20 Expression of Myelin-Specific CD8+ T Cells. Although typically
associated with B cells, CD20 is also expressed on a subset of
highly activated proinflammatory T cells and is typically found in
memory T cell populations (35, 36, 42). CD20+ T cells are
reported to be increased in MS patients (35, 36), are present in
MS lesions (43), and are reduced by anti-CD20 mAb therapies
(35, 42, 44). The expression of CD20 was therefore measured on
ex vivo antigen-specific CD8+ T cells (SI Appendix, Fig. S5A).
Interestingly, the frequencies of pooled myelin-specific CD20+
CD8+ T cells was significantly higher in MS patients (10.1 ±
2.7%) compared to control subjects (3.3 ± 1.1%), whereas there
were no differences in influenza-specific CD20+ CD8+ T cells
(5.0 ± 0.7% and 4.9 ± 1.2%, respectively) (Fig. 3A). The per-
centage of MOG181–189:HLA-A2 CD8
+ T cells expressing CD20
was significantly increased in MS patients (21.2 ± 7.8%) com-
pared to HLA allele-matched controls (0.0 ± 0.0%) (Fig. 3B).
There was also an increase in PLP45–53:HLA-A3 CD20
+ CD8+ T
cells in MS patients compared to controls that was nonsignificant
(18.7 ± 11.1% and 7.9 ± 3.8%, respectively; P = 0.08). This
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represented a substantial enrichment in CD20 expression in
comparison to the total frequency of CD20+ CD8+ T cells (5.5 ±
0.7% in MS patients; 4.4 ± 0.8% in controls). Influenza-specific
CD20+ CD8+ T cell populations exhibited a predominantly
memory phenotype, consistent with the known activated state of
CD20+ T cells (35, 36). The memory status of CD20-expressing
myelin-specific CD8+ T cells was variable, but with an overall
significant increase in myelin-specific memory CD20+ CD8+ T
cells in MS patients (53.7 ± 10.3%) compared to control subjects
(27.0 ± 9.7%) (SI Appendix, Fig. S5B). Thus, these findings pro-
vide further support that a greater proportion of myelin-specific
CD8+ T cells in MS patients have encountered antigen compared
to control subjects.
Effects of Anti-CD20 Treatment on Myelin-Specific CD8+ T Cells. Anti-
CD20 mAb therapies, including rituximab and ocrelizumab, have
become a mainstay of MS treatment due to their high efficacy
(45, 46). Since CD20 expression is increased in myelin-specific
CD8+ T cells in MS patients, we therefore asked whether these
T cells may be preferentially depleted following anti-CD20 mAb
treatment. The effect of anti-CD20 mAb was examined by com-
paring MS patients before (i.e., untreated) and after anti-CD20
mAb treatment (SI Appendix, Fig. S6A). There was no significant
effect on the overall (Fig. 4A) or individual (SI Appendix, Fig. S6 B
and C) frequencies of influenza- and myelin-specific CD8+ T cells
following anti-CD20 mAb treatment, with the exception of a small
reduction in M158–66-specific CD8
+ T cells (SI Appendix, Fig.
S6B). There was a significant reduction in the frequency of pooled
myelin-specific, but not influenza-specific CD20+ CD8+ T cells
following anti-CD20 mAb treatment (Fig. 4B). Anti-CD20 mAb
treatment was associated with significant reductions in the
percentages of MOG181–189:HLA-A2 CD20
+ CD8+ T cells and
nonsignificant reductions for PLP45–53:HLA-A3 (P = 0.11) and
CNP54–63:HLA-A3 (P = 0.14) (Fig. 4C). There was no significant
decrease in the percentages of total influenza- and myelin-specific
memory CD8+ T cells (Fig. 4D). Anti-CD20 mAb treatment
Fig. 1. Validation of myelin-specific CD8+ T cell epitopes. Overview of screening and confirmation of myelin-specific CD8+ T cells starting from pools of
myelin peptides (A). In this approach, PBMCs from a cohort of HLA-A2+ and HLA-A3+ untreated RR-MS patients were stimulated in vitro with pools of myelin
peptides (see Table 1 for tested peptides) for 1 wk. After staining with pools of cognate myelin pMHC I tetramers, tetramer-positive CD8+ T cells were sorted
and expanded with mitogen for 2 to 4 wk. Expanded cells were tested for specific binding to individual tetramers. Myelin antigens demonstrating tetramer
binding were then tested for functional reactivity to cognate antigen by cytokine production. Only those myelin epitopes demonstrating both specific
tetramer binding and functional reactivity were considered validated. A representative experiment (B) demonstrating identification of MOG181–189:HLA-A2
tetramer-positive CD8+ T cells. The HLA-A2–restricted influenza antigen M158–66 was used as an additional negative control to confirm specificity of MOG181–189
tetramer binding. The 5 myelin epitopes that were validated by tetramer binding and intracellular cytokine production to cognate antigen are shown (C).
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was associated with significant reductions in the percentage of
memory CD8+ T cells specific for MOG181–189:HLA-A2 and
CNP54–63:HLA-A3 with an increase in MAG509–517:HLA-A2
memory CD8+ T cells (Fig. 4E).
Discussion
Compelling evidence indicates that CD8+ T cells play an impor-
tant role in MS. CD8+ T cells are abundant and clonally expanded
in MS lesions (3–7), and certain MHC I alleles are linked with MS
susceptibility (15, 16). Indeed, it was recently shown that clonally
expanded CD8+ T cells are an early feature in the CSF of MS-
discordant monozygotic twins with subclinical neuroinflammation
(47). CD8+ T cells also are reduced by a number of MS disease-
modifying therapies (DMTs), including S1P receptor modulators,
which are correlated with reductions in biomarkers of CNS injury
(48). CD8+ T cells specific for myelin antigens are also pathogenic
in various EAE models (19–23). Prior efforts to study myelin-
specific CD8+ T cells have been hampered by technical limita-
tions and reliance on in vitro manipulation (24–30). In this study,
we employed pMHC I tetramer-based methods to unambiguously
Table 1. Study subject characteristics
Subjects N Age Female HLA-A2+/A3+
Active
relapse
Treatment
naive
Anti-CD20
mAb at T2
RR-MS 24 38 (18–54) 17 (71%) 15/11 10 (42%) 22 (92%) 9 (38%)
Control 17 31 (23–57) 10 (59%) 12/7 N/A N/A N/A
The number (N), mean age (and range), and percent female for RR-MS patients and control subjects used for
ex vivo CD8+ T cell frequency and phenotype analysis are shown. The number of HLA-A2+ and HLA-A3+ indi-
viduals (some codominantly expressed both MHC I alleles) for each group is shown. The number (and percent) of
RR-MS patients experiencing an active relapse within the past 30 d (confirmed by contrast-enhancing lesion on
MRI) and the percent who were naive to DMT at the time of their baseline sample acquisition are also shown.
The number (and percent) of RR-MS patients who were subsequently treated with anti-CD20 mAb and under-
went repeat analysis at follow-up time point 2 (T2) is shown.
Fig. 2. Ex vivo characterization of myelin-specific CD8+ T cells in the peripheral blood. Depiction of the experimental paradigm for ex vivo characterization of
tetramer-positive CD8+ T cells (A). PBMCs were collected from a cohort of untreated RR-MS patients and HLA allele-matched healthy controls. Purified CD8+
T cells were stained with a panel of tetramers with unique combinations of dual fluorophores containing at least one PE fluorophore, allowing enrichment
with anti-PE microbeads over a magnetic column. The frequencies and cell surface marker expression of each antigen-specific CD8+ T cell population were
then determined. The ex vivo frequencies of HLA-A2–restricted (B) and HLA-A3–restricted (C) myelin- and influenza-specific CD8+ T cells in MS patients (n = 15
HLA-A2; n = 11 HLA-A3) and control subjects (n = 12 HLA-A2; n = 7 HLA-A3) were compared (note: 2 of the MS patients and 2 of the control subjects were
HLA-A2+/A3+, thus accounting for the increased number of data points relative to the number of individual subjects listed in Table 1). The percentages of
pooled (D) or individual (E) memory influenza- and myelin-specific CD8+ T cells were compared between MS patients (n = 26 samples) and HLA allele-matched
controls (n = 19 samples). Memory status was defined by pooling all memory phenotypes (combined central memory CCR7+ CD45RA−, effector memory
CCR7−CD45RA−, and TEMRA CCR7− CD45RA+) in order to increase the number of cells for analysis). The circles represent individual samples (filled circles, MS;
open circles, control). For B and C, the line represents the mean ± SEM; for D and E, the top of the bar graph represents the mean ± SEM. Only samples with
detectable tetramer-positive CD8+ T cells were included for analysis. A 2-way ANOVA with multiple comparisons was used for comparisons between MS
patients and control subjects (*P < 0.05, **P = 0.002, and ***P = 0.001).
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identify myelin-specific CD8+ T cell populations directly from the
peripheral blood without in vitro stimulation or manipulation. In
this study, we identified 2 myelin determinants not previously
described in humans, MOG181–189:HLA-A2 and CNP54–63:HLA-
A3, as well as several previously reported myelin-specific
CD8+ T cell epitopes (21, 24, 25, 30). By using a highly sensitive
and specific combinatorial tetramer staining and enrichment
strategy, we showed that the ex vivo frequencies of myelin-
specific CD8+ T cells in the peripheral blood did not differ be-
tween MS patients and MHC I allele-matched control subjects.
These findings are consistent with reports that self-reactive
CD8+ T cells are present at similar frequencies in individuals
Fig. 3. CD20 expression of antigen-specific CD8+ T cells. The overall frequencies of total influenza- and myelin-specific CD20+ CD8+ T cells were compared
between MS patients (n = 26 samples) and control subjects (n = 19 samples) (A). The percentage of CD20-expressing CD8+ T cells was compared for all CD8+ T
cells as well as for each individual epitope between MS patients and controls (B). The circles represent individual samples (filled circles, MS; open circles,
control), the line represents the mean ± SEM in A, and the top of the bar graph represents the mean ± SEM in B. Only samples with detectable tetramer-
positive CD8+ T cells were included for analysis. A 2-way ANOVA with multiple comparisons was used for comparisons between MS patients and control
subjects (*P = 0.01; **P = 0.0002).
Fig. 4. Effects of anti-CD20 mAb treatment on antigen-specific CD8+ T cells. The frequencies of pooled influenza- and myelin-specific CD8+ T cells was
compared for untreated MS patients (n = 26 samples) and a subset of the same patient cohort subsequently treated with anti-CD20 mAb (n = 10 samples) (A).
The mean percentage of CD20+ CD8+ T cells specific for pooled influenza and myelin epitopes (B) or each individual epitope (C) was compared between
untreated MS patients and following anti-CD20 mAb treatment. The mean percentage of memory CD8+ T cells for pooled influenza and myelin epitopes (D)
or each individual epitope (E) before and after anti-CD20 mAb treatment is also shown. The circles represent individual samples (filled circles, untreated; open
circles, post-αCD20 mAb). For A and B, the line represents the mean ± SEM; for C–E, the top of the bar graph represents the mean ± SEM. Only samples with
detectable tetramer-positive CD8+ T cells were included for analysis in B–E. A mixed-effects model for repeated measures with multiple comparisons was used
for comparisons of untreated and anti-CD20 mAb-treated samples (*P < 0.05; **P ≤ 0.01).
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with and without autoimmune disease (39, 49) and reinforce the
principle that central tolerance does not completely eliminate all
self-reactive T cells. Despite the lack of quantitative differences,
we found an increased proportion of memory myelin-specific
CD8+ T cells in MS patients compared to control subjects,
indicating prior activation by antigen. In vitro expansion of
these myelin-specific CD8+ T cells revealed the production
of proinflammatory cytokines. Two of the epitopes we studied,
MOG181–189:HLA-A2 and PLP45–53:HLA-A3, are pathogenic in
humanized HLA transgenic mouse models of EAE (21, 22). In
addition, myelin-reactive human T cells have the capacity to
induce CNS inflammation in immunodeficient mice (50). These
findings therefore support the possibility that myelin-CD8+ T
cells may contribute to MS pathogenesis.
Although CD20 is a hallmark cell surface molecule expressed
by B cells and is the target for B cell-depleting therapy in MS, it
is now recognized that some T cells express CD20, which is expressed
by a higher proportion of CD8+ T cells compared to CD4+ T cells
(35, 36, 42, 51). CD8+ T cells expressing CD20 have been pre-
viously demonstrated to be highly activated proinflammatory
cytokine-producing memory T cells bearing CNS-homing chemo-
kine receptors and adhesion molecules (36, 42), thus highlighting
their pathogenic potential. In addition, CD20+ T cells have been
directly implicated in MS pathogenesis (35, 36, 43). The precise
mechanism(s) responsible for the benefit of anti-CD20 mAb in
MS is not entirely clear and may include effects on T cells (52, 53).
The finding that the frequency of CD20-expressing myelin-specific
CD8+ T cells is increased in MS patients compared to control
individuals is consistent with an increased activation state and
suggested that these cells could be targeted by anti-CD20 mAb
therapy. Indeed, our findings confirm that CD20-expressing
myelin-specific CD8+ T cells are preferentially depleted by
anti-CD20 mAb treatment. Similarly, the proportion of certain
memory myelin-specific CD8+ T cells was significantly reduced
following anti-CD20 mAb therapy, consistent with the memory
status of CD20+ CD8+ T cells. Surprisingly, the CD20 expres-
sion of influenza-specific CD8+ T cells was reduced to a lesser
degree by anti-CD20 mAb. The reason for this discrepancy is not
clear; however, it is important to note that the molecular mech-
anisms by which T cells express CD20 have not been fully eluci-
dated, and CD20+ T cell reconstitution occurs earlier (3 to 6 mo)
than for B cells (>6 mo) following anti-CD20 mAb treatment (35,
42). Most of the patients in the longitudinal arm of this study were
treated with anti-CD20 mAb 3 to 6 mo prior; therefore, it is pos-
sible that CD20+ CD8+ T cells specific for influenza recon-
stituted more quickly than those specific for myelin antigen.
Our study demonstrated an increase in memory myelin-specific
CD8+ T cells in MS patients. Given the inherent promiscuity of
the T cell receptor (54, 55), it is possible that the initial priming of
those T cells could be due to a cross-reactive antigen (e.g., viral
antigen). Nonetheless, these findings point to increased antigen
experience of CD8+ T cells capable of responding to myelin an-
tigens in MS patients compared to healthy controls. The under-
lying cause for the increase in myelin-specific CD8+ T cell
activation in MS patients remains unclear. Although HLA-A2 and
HLA-A3 are implicated in MS susceptibility, it is important to
note that the phenotypic differences observed in our study cannot
be explained by the presence of HLA-A2 and HLA-A3 because
MS patients and control subjects were matched by these alleles.
Due to the stringent criteria employed for myelin epitope val-
idation, this study focused on a relatively limited number of myelin
CD8+ T cell determinants. It is therefore possible that other my-
elin CD8+ T cell epitopes may exist and show unique differences in
frequency in MS patients. While myelin-specific CD4+ T cells have
been directly linked to MS pathogenesis (18, 56), a similar role for
myelin-specific CD8+ T cells remains unknown and is outside the
scope of the present study. Although many studies support a
proinflammatory role of myelin-specific CD8+ T cells in MS and
EAE, it remains possible that they may have a regulatory or sup-
pressive function in certain circumstances (57–59). It is also
important to acknowledge that the antigen specificity of clonally
expanded T cells in MS is not known at this time, and it is possible
that other self- or even non–self-antigens may be targeted (59).
Indeed, it was recently reported that CNS-infiltrating CD4+ T cell
clones recognize ubiquitously expressed self-antigens (56, 60).
Deciphering which CD8+ T cells are relevant to the disease
process and the unique characteristics they possess is a critical
hurdle to our understanding of MS. In this study, a pMHC I
tetramer-based approach was used to characterize multiple myelin-
specific CD8+ T cell populations ex vivo, which demonstrated
evidence of increased activation in MS patients. This unique ac-
tivation state of myelin-specific CD8+ T cells was associated with
their preferential depletion by anti-CD20 mAb therapy. These
data provide further evidence that myelin-specific CD8+ T cells
play a central role in MS pathogenesis. Selective targeting of these
activated myelin-specific CD8+ T cells could represent an attrac-
tive approach to MS treatment.
Materials and Methods
Human Subjects and Samples. All investigations were institutional review
board approved (University of California, San Francisco, Committee on Hu-
man Research), and all participants provided written informed consent. Pe-
ripheral blood was collected from healthy controls (no known history of
neurologic disease, immunocompromised state, or immunosuppression) and
RR-MS patients as defined by 2017 McDonald Criteria. Ninety-two percent of
RR-MS patients were naive to DMT, and the remaining patients had been off
DMTs greater than 3 mo at the time of baseline sample collection (Table S1).
For patients experiencing recent relapses, blood samples were collected af-
ter more than 30 d of last steroid treatment. One hundred to 140 mL of
whole blood were collected from each subject. PBMCs were isolated by Ficoll
separation and were frozen in 10% DMSO and 90% FBS in liquid nitrogen
until the day of experimentation. Subjects were screened for HLA-A2 and
HLA-A3 status by serotyping using the antibody clones BB7.2 (BioLegend)
and GAP.A3 (eBioscience), respectively. Genetic confirmation was done by
haplotyping of the MHC I A locus at 4× resolution (Histogenetics). PBMCs
from 11 untreated HLA-A2+ and/or HLA-A3+ RR-MS patients were used in
the initial epitope screening experiments. A second cohort of RR-MS (n = 24)
and healthy donors (n = 17) matched for HLA-A2+ and HLA-A3+ status was
used for ex vivo tetramer enrichment and phenotyping. A subset of the
RR-MS patients (n = 9) were subsequently treated with anti-CD20 mAb
(rituximab or ocrelizumab) and underwent a second blood collection 1 to
6 mo after their most recent infusion.
Antigens. Candidate myelin epitopes were selected from the myelin proteins
MBP, PLP, MOG, MAG, and CNP. Using a combination of the epitope pre-
diction databases IEDB and SYFPEITHI, 31 and 24 candidate myelin peptides
were identified and synthesized to >95% purity (Genemed Synthesis) for
HLA-A2 and HLA-A3, respectively (SI Appendix, Table S1). The influenza
peptides M158–66 (HLA-A2) and NP265–273 (HLA-A3) were used as control non-
self-antigens. Myelin peptide:MHC relative binding of HLA-A2– and HLA-
A3–expressing cell lines, T2-A2 (ATCC) and T2-A2/A3 (coexpressing HLA-A2
and HLA-A3; courtesy of Dr. Elizabeth Jaffee, Johns Hopkins, Baltimore,
MD), was measured based on a previously published protocol (61). In brief,
1 × 105 T2 cells were washed and resuspended in serum-free RPMI and
pulsed overnight with 10 μg/mL of the indicated myelin peptide or no
peptide in an incubator at 37 °C. The influenza peptides M158–66 and
NP265–273 were used as positive control reference peptides for HLA-A2 and
HLA-A3, respectively. T2 cells were washed and stained with HLA-A2 FITC (BB7.2)
or HLA-A3 APC (GAP.A3) and washed again before collection by flow cytometry
(LSRFortessa). The surface expression of HLA-A2 and HLA-A3 was measured by
mean fluorescent intensity (MFI). The percent relative binding was calculated as
[(MFImyelin peptide −MFIno peptide)/(MFIreference peptide − MFIno peptide)] × 100,
as shown in SI Appendix, Fig. S1.
Tetramer Generation and Staining. Ultraviolet (UV) photolabile pMHC I
monomers for HLA-A2 and HLA-A3 were obtained from the NIH Tetramer
Core. All pMHC I tetramers were generated by UV-ligand exchange as pre-
viously described (62). Tetramerization was carried out using streptavidin
conjugated to fluorophores PE (Life Technologies), APC (Life Technologies),
BV421 (BioLegend), or PE-CF94 (BioLegend). For all combinatorial tetramer
staining experiments (see below), 500 μM D-biotin was added to each
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tetramer to quench any possible unloaded biotin-binding sites on strepta-
vidin to prevent unintended binding of excess pMHC complexes to the in-
correct fluorophore (33). All T cell samples were CD8 purified to greater than
90% purity by negative selection (human CD8+ T cell isolation kit; Miltenyi)
prior to tetramer staining. CD8+ T cells were treated with 100 nM dasatinib
(StemCell) for 30 min at 37 °C followed by staining (no wash step) with the
indicated tetramers (final concentration, 2 to 3 μg/mL) for 30 min at room
temperature. Tetramers were pooled together just prior to tetramer stain-
ing. Pairs of cognate antigen tetramers in dual fluorophores were used for
all tetramer staining in order to improve binding specificity. Tetramers were
used within 2 mo of synthesis for epitope screening experiments, and within
1 wk for ex vivo tetramer enrichment experiments. Cells were washed in
FACS buffer (1× DPBS without calcium or magnesium, 0.1% sodium azide,
2 mM EDTA, 1% FBS) or sort buffer (1× DPBS without calcium or magnesium,
2 mM EDTA, 1% FBS, 0.22 μm sterile filtered), and then stained with anti-
CD8 PECy7 (eBioscience; SK1) or Alexa 700 (BioLegend; SK1), a PerCP/Cy5.5
dump antibody mixture containing anti-CD4 (BioLegend; RPA-T4), anti-
CD14 (BioLegend; HCD14), anti-CD16 (BioLegend; B73.1), and anti-CD19
(BioLegend; HIB19), and Aqua506 viability dye (Life Technologies), washed, and
collected by flow cytometry (LSRFortessa). For the ex vivo tetramer enrich-
ment experiments, anti–CD45RA-APC/Fire750 (BioLegend; HI100), anti-CCR7
PECy7 (BioLegend; G043H7), and anti-CD20 FITC (BioLegend; 2H7) were also
used. CD8+ T cells were identified by lymphocytes, single cells (FSC-H, FSC-W),
dump channel negative, live CD8+ cells (SI Appendix, Fig. S3A).
Expansion of Myelin-Specific CD8+ T Cells. PBMCs (6 × 106 to 2.4 × 107) from
untreated MS patients were stimulated with pools of 5 myelin peptides (final
concentration 10 μg/mL each) with recombinant human IL-2 (10 ng/mL) in 96-
well plates (5 × 105 cells/well) and incubated (37 °C, 5% CO2) for 1 wk. All T cell
culture was done using RPMI 1640 with L-glutamine containing 10% heat-
inactivated FBS (Life Technologies), 55 nM 2-mercaptoethanol (Life Technolo-
gies), penicillin/streptomycin/glutamine (Life Technologies), 1 mM sodium py-
ruvate (Life Technologies), MEM nonessential amino acids (Life Technologies),
and MEM vitamin solution (Life Technologies). Peptides tested were those in-
dicated in SI Appendix, Table S1. Wells from individual patient samples were
pooled together, CD8 purified, treated with dasatinib, stained with pools of
tetramers (containing the same cognate antigens from the primary stimula-
tion), followed by surface staining as detailed above. Tetramer-positive
CD8+ T cells were sorted on a FACSAria cell sorter into a 96-well round-
bottom plate (50 to 100 cells per well). Sorted cells were stimulated for 2 wk
with 2 μg/mL PHA-L (Sigma-Aldrich), 10 ng/mL recombinant human IL-2
(BioLegend), and irradiated (3,000 rad) allogenic feeder PBMCs. Cells were
refed with half volume of fresh media and IL-2 every 3 to 4 d.
Intracellular Cytokine Stimulation. T2 cells (1 × 105 cells per condition)
expressing HLA-A3 and/or HLA-A2 were pulsed overnight with 10 μg/mL of
the indicated myelin peptide or no antigen. Myelin tetramer-positive CD8+
T cells (5 × 104 to 2 × 105) were added to the pulsed T2 cells (total volume,
100 μL) and stimulated for 6 h in the presence of 1:500 GolgiStop (BD), 1:500
GolgiPlug (BD), and 1:200 CD28/CD49d (FastImmune; BD). Cells were washed
with FACS buffer and stained with the cell surface antibodies as above (anti-
CD8, dump channel antibody mixture, and live/dead dye). Cells were washed,
fixed, and stained with antibodies for intracellular cytokines in permeabiliza-
tion buffer. Intracellular antibodies included IFN-γ Alexa 647 (BioLegend; 4S.B3),
TNFα Alexa 488 (BioLegend; Mab11), IL-2 BV421 (BioLegend; MQ1-17H12), GM-
CSF PE (BioLegend; BVD2-21C11), CD107a APC/Cy7. Cells were then washed and
collected on an LSRFortessa.
Combinatorial Tetramer Staining and Enrichment. In total, 3–5 × 107 PBMCs
from each human subject were thawed, washed, and CD8 purified by neg-
ative selection. The frequencies of antigen-specific CD8+ T cells were calcu-
lated as previously described (31, 63). After resuspending the purified
CD8+ T cells in a precise volume of sort buffer (typically 100 to 120 μL), 5 μL
was removed for counting with 123count eBeads (Invitrogen) in order to
determine the total input number of CD8+ T cells (MS mean, 1.5 × 106
CD8+ T cells; control mean, 1.9 × 106 CD8+ T cells). An additional 5 μL was
used for cell surface staining with anti-CD8, dump channel antibodies,
CD45RA, CCR7, CD20, and viability dye. The remaining cells were used for
tetramer enrichment and treated for 30 min with 100 nM dasatinib as
above. CD8+ T cells from each human sample were stained with pools of
HLA-A2– or HLA-A3–restricted myelin and influenza-specific tetramers.
Staining for each antigen-specific tetramer was performed using dual fluo-
rophores (SI Appendix, Fig. S2), where at least one of the fluorophores
contained PE in order to allow enrichment with anti-PE magnetic beads.
Tetramer-stained CD8+ T cells were washed, resuspended in 200 μL of sort
buffer, and incubated with 50 μL of anti-PE magnetic microbeads (Miltenyi)
for 20 min at 4 °C. Cells were washed and enriched over LS columns
(Miltenyi) as per the manufacturer’s instructions. The tetramer-enriched cells
were resuspended in a precise volume of sort buffer (typically 100 to 120 μL),
and 5 μL was removed for counting with 123count beads in order to de-
termine the total number of antigen-positive CD8+ T cells. The remaining
cells were stained with same cell surface staining mixture as used for the
preenriched samples. In addition to the gating strategy described above, a
stringent tetramer gating strategy was employed (SI Appendix, Fig. S3), as
previously described (33). In brief, tetramer-positive CD8+ T cells were gated
on the dual fluorophores specified for each antigen (SI Appendix, Table S2).
Only those tetramer-positive CD8+ T cells that were negative for the other
fluorophores were considered genuine tetramer-positive cells. Thus, cells
that stained positive with more or less than 2 fluorophores were excluded
from the analysis.
Statistics. Statistical analyses and graphing were performed with GraphPad
Prism, version 8. A 2-way ANOVA with multiple comparisons (corrected for
false-discovery rate with 2-stage step-up method of Benjamini, Krieger, and
Yekutieli) was used for comparisons between MS patients and control sub-
jects. A mixed-effects model for repeated measures with multiple compari-
sons (corrected for false-discovery rate with 2-stage step-up method of
Benjamini, Krieger, and Yekutieli) was used for comparisons of untreated and
anti-CD20 mAb-treated samples. Values of P ≤ 0.05 were considered
statistically significant.
Data Availability. All data and protocols used to support the findings of this
study have been included in the manuscript and SI Appendix.
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